2021-2032 All Rights Reserved. Online Journal of Veterinary Research.  You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to onlinejournals@gmail.com publications. This article may be copied once but may not be, reproduced or  re-transmitted without the express permission of the editors. Linking: To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.


Online Journal of Veterinary Research


Volume 25(2): 156-160, 2021.

Docking model for NS3-4A protein to Hepatitis C virus.


R Shanmugam1, K Mani 1, B Vijay Kumar 2


BRT lab, Department of Bioinformatics2, Department of Botany, PSG College of Arts and Science Coimbatore,India 1




Shanmugam R, Mani K, Vijay Kumar B., Docking model for NS3-4A proteins to Hepatitis C virus, Onl J Vet Res., 25(2): 156-160, 2021. Non-structural proteins of Hepatitis C virus NS3-4A are vital for viral polyprotein processing and replication and thus a potential therapeutic target. We modeled NS3/4A with serine protease inhibitors extracted from NCBI and QSAR and docked serine proteinase benzamidine with Aphyllophorales fungus through Discovery studio. Ramachandran plot showed 95.7% of residues in favoured region, 2.7% in allowed region and 1.6% were outliers. We found 28 serine protease inhibitors used for docking finding that 2,3,4-trihydroxy-6-hydroxymethyl benzaldehyde (Fomecin A) yielded a high score of 38.002 at site 2. Fomecin A from Pyrofomes dimidoffi heart rot fungus has phage and anti-bacterial activity and could be a lead antiviral for NS3/4A of Hepatitis C virus. Future research should focus on Fomecin A cell lines and clinical trials.

Key words: Hepatitis c virus, Docking, TSAR, and ADME/TOX, serine protease inhibitors, WHATCHECK report, Fomecin A.